Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies.

NCT00776165 is registered in ClinicalTrials.gov with Shantha Biotechnics Limited as lead sponsor.

NCT NCT00776165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies.
Lead sponsor
Shantha Biotechnics Limited
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
September 30, 2009
Enrollment
126 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia